Serum urate and probability of dopaminergic deficit in early “Parkinson's disease”
Identifieur interne : 000339 ( Main/Curation ); précédent : 000338; suivant : 000340Serum urate and probability of dopaminergic deficit in early “Parkinson's disease”
Auteurs : Michael A. Schwarzschild [États-Unis] ; Kenneth Marek [États-Unis] ; Shirley Eberly [États-Unis] ; David Oakes [États-Unis] ; Ira Shoulson [États-Unis] ; Danna Jennings [États-Unis] ; John Seibyl [États-Unis] ; Alberto Ascherio [États-Unis]Source :
- Movement Disorders [ 0885-3185 ] ; 2011-08-15.
English descriptors
Abstract
The objective of this study was to investigate whether higher levels of urate, an antioxidant linked to a lower likelihood of developing Parkinson's disease, is also a predictor of having a dopamine transporter brain scan without evidence of dopaminergic deficit. In a cross‐sectional study of 797 mildly affected, untreated parkinsonian subjects diagnosed with early Parkinson's disease in the Parkinson Research Examination of CEP‐1347 Trial, we investigated the relationship at baseline between serum urate and striatal dopamine transporter density, determined by single‐photon emission computed tomography of iodine‐123‐labeled 2‐β‐carboxymethoxy‐3‐β‐(4‐iodophenyl)tropane uptake. A scan without evidence of dopaminergic deficit was defined as lowest putamen iodine‐123‐labeled 2‐β‐carboxymethoxy‐3‐β‐(4‐iodophenyl)tropane > 80% age‐expected putamen dopamine transporter density. The odds of having a scan without evidence of dopaminergic deficit rose across increasing quintiles of urate level, with an age‐ and sex‐adjusted odds ratio of 3.2 comparing the highest to the lowest urate quintile (95% confidence interval, 1.5–7.2; P for trend = .0003), and remained significant after adjusting for potential confounding factors. The association was significant in men but not women, regardless of whether common or sex‐specific quintiles of urate were used. Higher levels of urate were associated with a greater likelihood of a scan without evidence of dopaminergic deficit among subjects with early untreated parkinsonism in the Parkinson Research Examination of CEP‐1347 Trial. The findings support the diagnostic utility of urate in combination with other determinants. © 2011 Movement Disorder Society
Url:
DOI: 10.1002/mds.23741
Links toward previous steps (curation, corpus...)
- to stream Main, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000392
Links to Exploration step
ISTEX:9217CF0BE19CFAC02CAEDB77C00779BAEE40BFC6Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Serum urate and probability of dopaminergic deficit in early “Parkinson's disease”</title><author><name sortKey="Schwarzschild, Michael A" sort="Schwarzschild, Michael A" uniqKey="Schwarzschild M" first="Michael A." last="Schwarzschild">Michael A. Schwarzschild</name><affiliation wicri:level="1"><mods:affiliation>Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts</wicri:regionArea></affiliation></author><author><name sortKey="Marek, Kenneth" sort="Marek, Kenneth" uniqKey="Marek K" first="Kenneth" last="Marek">Kenneth Marek</name><affiliation wicri:level="1"><mods:affiliation>Institute for Neurodegenerative Disorders, New Haven, Connecticut, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Institute for Neurodegenerative Disorders, New Haven, Connecticut</wicri:regionArea></affiliation></author><author><name sortKey="Eberly, Shirley" sort="Eberly, Shirley" uniqKey="Eberly S" first="Shirley" last="Eberly">Shirley Eberly</name><affiliation wicri:level="1"><mods:affiliation>Departments of Neurology and Biostatistics, University of Rochester, Rochester, New York, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Departments of Neurology and Biostatistics, University of Rochester, Rochester, New York</wicri:regionArea></affiliation></author><author><name sortKey="Oakes, David" sort="Oakes, David" uniqKey="Oakes D" first="David" last="Oakes">David Oakes</name><affiliation wicri:level="1"><mods:affiliation>Departments of Neurology and Biostatistics, University of Rochester, Rochester, New York, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Departments of Neurology and Biostatistics, University of Rochester, Rochester, New York</wicri:regionArea></affiliation></author><author><name sortKey="Shoulson, Ira" sort="Shoulson, Ira" uniqKey="Shoulson I" first="Ira" last="Shoulson">Ira Shoulson</name><affiliation wicri:level="1"><mods:affiliation>Departments of Neurology and Biostatistics, University of Rochester, Rochester, New York, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Departments of Neurology and Biostatistics, University of Rochester, Rochester, New York</wicri:regionArea></affiliation></author><author><name sortKey="Jennings, Danna" sort="Jennings, Danna" uniqKey="Jennings D" first="Danna" last="Jennings">Danna Jennings</name><affiliation wicri:level="1"><mods:affiliation>Institute for Neurodegenerative Disorders, New Haven, Connecticut, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Institute for Neurodegenerative Disorders, New Haven, Connecticut</wicri:regionArea></affiliation></author><author><name sortKey="Seibyl, John" sort="Seibyl, John" uniqKey="Seibyl J" first="John" last="Seibyl">John Seibyl</name><affiliation wicri:level="1"><mods:affiliation>Institute for Neurodegenerative Disorders, New Haven, Connecticut, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Institute for Neurodegenerative Disorders, New Haven, Connecticut</wicri:regionArea></affiliation></author><author><name sortKey="Ascherio, Alberto" sort="Ascherio, Alberto" uniqKey="Ascherio A" first="Alberto" last="Ascherio">Alberto Ascherio</name><affiliation wicri:level="1"><mods:affiliation>Departments of Epidemiology and Nutrition, Harvard School of Public Health, Boston, Massachusetts, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Departments of Epidemiology and Nutrition, Harvard School of Public Health, Boston, Massachusetts</wicri:regionArea></affiliation><affiliation wicri:level="1"><mods:affiliation>Channing Laboratory, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Channing Laboratory, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:9217CF0BE19CFAC02CAEDB77C00779BAEE40BFC6</idno><date when="2011" year="2011">2011</date><idno type="doi">10.1002/mds.23741</idno><idno type="url">https://api.istex.fr/document/9217CF0BE19CFAC02CAEDB77C00779BAEE40BFC6/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000392</idno><idno type="wicri:Area/Main/Curation">000339</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Serum urate and probability of dopaminergic deficit in early “Parkinson's disease”</title><author><name sortKey="Schwarzschild, Michael A" sort="Schwarzschild, Michael A" uniqKey="Schwarzschild M" first="Michael A." last="Schwarzschild">Michael A. Schwarzschild</name><affiliation wicri:level="1"><mods:affiliation>Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts</wicri:regionArea></affiliation></author><author><name sortKey="Marek, Kenneth" sort="Marek, Kenneth" uniqKey="Marek K" first="Kenneth" last="Marek">Kenneth Marek</name><affiliation wicri:level="1"><mods:affiliation>Institute for Neurodegenerative Disorders, New Haven, Connecticut, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Institute for Neurodegenerative Disorders, New Haven, Connecticut</wicri:regionArea></affiliation></author><author><name sortKey="Eberly, Shirley" sort="Eberly, Shirley" uniqKey="Eberly S" first="Shirley" last="Eberly">Shirley Eberly</name><affiliation wicri:level="1"><mods:affiliation>Departments of Neurology and Biostatistics, University of Rochester, Rochester, New York, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Departments of Neurology and Biostatistics, University of Rochester, Rochester, New York</wicri:regionArea></affiliation></author><author><name sortKey="Oakes, David" sort="Oakes, David" uniqKey="Oakes D" first="David" last="Oakes">David Oakes</name><affiliation wicri:level="1"><mods:affiliation>Departments of Neurology and Biostatistics, University of Rochester, Rochester, New York, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Departments of Neurology and Biostatistics, University of Rochester, Rochester, New York</wicri:regionArea></affiliation></author><author><name sortKey="Shoulson, Ira" sort="Shoulson, Ira" uniqKey="Shoulson I" first="Ira" last="Shoulson">Ira Shoulson</name><affiliation wicri:level="1"><mods:affiliation>Departments of Neurology and Biostatistics, University of Rochester, Rochester, New York, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Departments of Neurology and Biostatistics, University of Rochester, Rochester, New York</wicri:regionArea></affiliation></author><author><name sortKey="Jennings, Danna" sort="Jennings, Danna" uniqKey="Jennings D" first="Danna" last="Jennings">Danna Jennings</name><affiliation wicri:level="1"><mods:affiliation>Institute for Neurodegenerative Disorders, New Haven, Connecticut, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Institute for Neurodegenerative Disorders, New Haven, Connecticut</wicri:regionArea></affiliation></author><author><name sortKey="Seibyl, John" sort="Seibyl, John" uniqKey="Seibyl J" first="John" last="Seibyl">John Seibyl</name><affiliation wicri:level="1"><mods:affiliation>Institute for Neurodegenerative Disorders, New Haven, Connecticut, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Institute for Neurodegenerative Disorders, New Haven, Connecticut</wicri:regionArea></affiliation></author><author><name sortKey="Ascherio, Alberto" sort="Ascherio, Alberto" uniqKey="Ascherio A" first="Alberto" last="Ascherio">Alberto Ascherio</name><affiliation wicri:level="1"><mods:affiliation>Departments of Epidemiology and Nutrition, Harvard School of Public Health, Boston, Massachusetts, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Departments of Epidemiology and Nutrition, Harvard School of Public Health, Boston, Massachusetts</wicri:regionArea></affiliation><affiliation wicri:level="1"><mods:affiliation>Channing Laboratory, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Channing Laboratory, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts</wicri:regionArea></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2011-08-15">2011-08-15</date><biblScope unit="volume">26</biblScope><biblScope unit="issue">10</biblScope><biblScope unit="page" from="1864">1864</biblScope><biblScope unit="page" to="1868">1868</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">9217CF0BE19CFAC02CAEDB77C00779BAEE40BFC6</idno><idno type="DOI">10.1002/mds.23741</idno><idno type="ArticleID">MDS23741</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term><term>biomarker</term><term>diagnosis</term><term>dopamine transporter</term><term>neuroimaging</term><term>urate</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The objective of this study was to investigate whether higher levels of urate, an antioxidant linked to a lower likelihood of developing Parkinson's disease, is also a predictor of having a dopamine transporter brain scan without evidence of dopaminergic deficit. In a cross‐sectional study of 797 mildly affected, untreated parkinsonian subjects diagnosed with early Parkinson's disease in the Parkinson Research Examination of CEP‐1347 Trial, we investigated the relationship at baseline between serum urate and striatal dopamine transporter density, determined by single‐photon emission computed tomography of iodine‐123‐labeled 2‐β‐carboxymethoxy‐3‐β‐(4‐iodophenyl)tropane uptake. A scan without evidence of dopaminergic deficit was defined as lowest putamen iodine‐123‐labeled 2‐β‐carboxymethoxy‐3‐β‐(4‐iodophenyl)tropane > 80% age‐expected putamen dopamine transporter density. The odds of having a scan without evidence of dopaminergic deficit rose across increasing quintiles of urate level, with an age‐ and sex‐adjusted odds ratio of 3.2 comparing the highest to the lowest urate quintile (95% confidence interval, 1.5–7.2; P for trend = .0003), and remained significant after adjusting for potential confounding factors. The association was significant in men but not women, regardless of whether common or sex‐specific quintiles of urate were used. Higher levels of urate were associated with a greater likelihood of a scan without evidence of dopaminergic deficit among subjects with early untreated parkinsonism in the Parkinson Research Examination of CEP‐1347 Trial. The findings support the diagnostic utility of urate in combination with other determinants. © 2011 Movement Disorder Society</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000339 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Curation/biblio.hfd -nk 000339 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Curation
|type= RBID
|clé= ISTEX:9217CF0BE19CFAC02CAEDB77C00779BAEE40BFC6
|texte= Serum urate and probability of dopaminergic deficit in early “Parkinson's disease”
}}
| This area was generated with Dilib version V0.6.23. |  |